COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review
Eşkazan AE. Evolving treatment strategies in CML – moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? Br J Clin Pharmacol. 2018;84(8):1635–8.
Hochhaus A, Baccarani M, Silver RT, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84.
Silondae R, Harjianti T, Saleh S, et al. A Three-Years Survival Rates of Chronic Myeloid Leukemia Patients with Targeted Therapy. Indian J Public Heal Res Dev. 2020;11(1):1436–42.
Reksodiputro, ArryHarryanto, Atmakusuma, et al. Chronic Myeloid Leukemia in Indonesia. Jakarta: Dharmais Hospital National Cancer Centre. 2018.
Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(2):1099–104.
Breccia M, Abruzzese E, Bocchia M, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia. 2020;34(8):2260–1.
Nesr G, Saleem Z, Arami S. Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience. J Med Virol. 2022;94(4):1274–6.
Ibrahm RI, Chatzis GP, Korayem MA, et al. Management of chronic myeloid leukemia with sever covid 19: A case report. Open Access Maced J Med Sci. 2020;8(T1):304–8.
Yılmaz U, Pekmezci A, Gül Y, et al. COVID-19 in chronic-phase chronic myeloid leukemia patients: A single-center survey from Turkey. Turkish J Hematol. 2021;38(1):79–81.
Li W, Wang D, Guo J, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020;34(7):1799–804.
Rea D, Mauro MJ, Cortes JE, et al. COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Blood. 2020;136(Supplement 1):46–7.
Radich JP, Kok CH, Chelysheva EY, et al. A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income. Blood. 2022;140(Supplement 1):9617–9.
Kurniawan A, Lugito NPH, Baskoro BA, et al. Management of Cancer Patients during Coronavirus Disease 2019 Pandemic: A Literature Review. Indones J Cancer. 2020;14(2):69.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.
Coleman CM, Sisk JM, Mingo RM,et al. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924–33.
Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99(5):619–30.
Galimberti S, Petrini M, Baratè C, et al. Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. Front Oncol. 2020;10(September):1–9.
Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8(April):1–12.
Jasielec JK, Larson RA. Dasatinib-related pulmonary toxicity mimicking an atypical infection. J Clin Oncol. 2016;34(6):e46–8.
Eskazan AE, Soysal T, Ongoren S, et al. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011;28(3):2011.
Haguet H, Bouvy C, Delvigne AS, et al. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020;11(July):1–11.
Eskazan AE. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. Br J Clin Pharmacol. 2020;86(April):1790–2.
Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int [Internet]. 2020;14(5):881–3. Available from: https://doi.org/10.1007/s12072-020-10077-3
Béchade D, Chakiba C, Desjardin M,et al. Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications. Bull Cancer [Internet]. 2018;105(3):290–8. Available from: http://dx.doi.org/10.1016/j.bulcan.2017.11.015
Backman JT, Filppula AM, Niemi M, et al. Role of Cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241.
Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173–81.
Michael Mauro, Druker B, Radich J, et al. COVID-19 and CML: Frequently Asked Questions [Internet]. American Society of Hematology. 2021 [cited 2022 Apr 21]. Available from: https://www.hematology.org/covid-19/covid-19-and-cml
Rasyid H, Sangkereng A, Harjianti T, et al. Impact of age to ferritin and neutrophil- lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in 19 patients in Makassar , Indonesia. Physiol Rep. 2021;9(10):1–10.
Zhang H, Han H, He T, et al. Clinical Characteristics and Outcomes of COVID-19 – Infected Cancer Patients : A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2021;113:371–80.
Sandoval M, Nguyen DT, Vahidy FS, et al. Risk factors for severity of COVID-19 in hospital patients age 18-29 years. PLoS One [Internet]. 2021;16(7 July):1–22. Available from: http://dx.doi.org/10.1371/journal.pone.0255544
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.